DALLAS, March 4, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Questcor Pharmaceuticals Inc. (Nasdaq:QCOR). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/QCOR
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Questcor Pharmaceuticals Inc. (QCOR), a specialty biopharmaceutical company, focuses on providing prescription drugs for the treatment of rare central nervous system and inflammatory diseases and disorders. The Company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (MS) and the treatment of nephrotic syndrome (NS). H.P. Acthar Gel is also used in treating patients with infantile spasms (IS), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. QCOR also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Message Board Search for QCOR: http://www.boardcentral.com/boards/QCOR
In the report, the analyst notes:
"QCOR reported solid financial results for the fourth quarter, with sales showing positive growth in the MS market. In addition, QCOR president and CEO Don Bailey stated that there are preliminary indications that Acthar may also begin to be adopted in the NS market, which is much larger than either the IS or MS markets.
"According to QCOR executive vice president Steve Cartt, the Company's initiatives to educate MS specialists about the treatment benefits of Acthar have resulted in a tripling in MS prescriptions year over year. Cartt also noted that spontaneous IS prescriptions during the fourth quarter rebounded to 140 new paid prescriptions from a low level of 119 in the third quarter."
To read the entire report visit: http://www.stockpreacher.com/n/QCOR
See what investors are saying about QCOR at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com.
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.